The CEO resigned for personal reasons.
Array BioPharma has appointed board chairman Kyle Lefkoff as interim head until a permanent replacement is found. The company will seek a leader to push its products from the clinic to the market.
The biopharmaceutical firm is focused on the discovery, development and commercialisation of targeted small-molecule drugs to treat cancer and inflammatory diseases. The company has nine drugs in Phase II clinical trials and USD3.4bn (EUR2.7bn) in potential milestone payments under its partnerships.
(USD1 = EUR0.781)
Atisama Therapeutics reports progress in Phase 1 study of RB042
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
GSK secures China approval for Exdensur to treat nasal polyp condition
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
Alloy Therapeutics and Biogen expand partnership with multi-target antisense collaboration